TURNSTONE BIOLOGICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.61 USD | -0.76% |
|
+0.38% | +2.55% |
| 05-13 | Turnstone Biologics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-16 | Turnstone Biologics Corp. Announces Board Changes | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 58.77 | 60.37 | - | - |
| Enterprise Value (EV) 1 | 58.77 | 60.37 | 60.37 | 60.37 |
| P/E ratio | -0.53 x | -0.9 x | -0.87 x | -0.87 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 3.04 x | - | - | - |
| EV / Revenue | 3.04 x | - | - | - |
| EV / EBITDA | -1.05 x | -0.73 x | -0.56 x | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 23,093 | 23,128 | - | - |
| Reference price 2 | 2.545 | 2.610 | 2.610 | 2.610 |
| Announcement Date | 22/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 19.31 | - | - | - |
| EBITDA 1 | - | -56.23 | -82.62 | -108.6 | - |
| EBIT 1 | - | -59.03 | -84.75 | -100.4 | -111 |
| Operating Margin | - | -305.77% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -55.49 | -80.32 | -85.95 | -111 |
| Net income 1 | -30.83 | -55.2 | -80.47 | -99.34 | -112.6 |
| Net margin | - | -285.92% | - | - | - |
| EPS 2 | -1.560 | -4.780 | -2.910 | -3.010 | -3.000 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 15/05/23 | 22/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -17.86 | -20.69 | -21.72 | -19.75 | -22.59 | -22 | -22 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -16.62 | -19.61 | -20.25 | -20.43 | -20.03 | -21.2 | -21.39 |
| Net income 1 | -21.52 | -17.32 | -16.45 | -19.63 | -21.18 | -18.67 | -21 | -21.2 | -21.39 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -7.560 | -1.000 | - | -0.8500 | -0.8400 | -0.6550 | -0.6800 | -0.5900 | -0.5900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 01/09/23 | 13/11/23 | 22/03/24 | 13/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -77.1% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 15/05/23 | 22/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.61
USD
Average target price
12.67
USD
Spread / Average Target
+385.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.55% | 60.37M | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- TSBX Stock
- Financials Turnstone Biologics Corp.
